Sevasemten is an allosteric inhibitor of skeletal muscle myosin inhibition with IC50s of ≤10 μM (skeletal), >100 μM (cardiac), respectively[1][2].
[1]. Russell Alan, et al. Preparation of substituted pyridazinones for use in the treatment of neuromuscular diseases: World Intellectual Property Organization, WO2021231615. 2021-11-18.
[2]. WHO Drug Information-World Health Organization (WHO).
















